Medicare for All is Medicare for None

 

Most seniors like their Medicare. While it is far from free, it does cost less than private health insurance because it is federally subsidized. Since nearly every doctor accepts Medicare, there is rarely any difficulty finding access to healthcare.

Therefore, when people hear progressives like Vermont Senator Bernie Sanders speak about his socialized medicine program called Medicare for All, they believe he simply wants to extend the same healthcare benefits to all Americans. Nothing could be further from the truth.

Recently, I had lunch with an old friend and attorney and we discussed this very issue. His comments about Medicare for All revealed many misconceptions about what that would mean to our healthcare. It occurred to me that if this educated man could be misinformed, many others would be, too. To address this misinformation, I have listed some of his questions and their answers:

If Medicare is good for seniors, won’t Medicare for All be good for everyone?

Although Medicare is mostly funded by taxpayers, it is not strictly a government system. It was formed originally by providing a standard benefit package offered by Blue Cross in 1965. It has always been privately administered, mostly by Blue Cross, which continues to provide private insurance to non-seniors. In recent years, one third of all seniors are enrolled in plans offered by private insurers such as Cigna, Humana, and United Healthcare under a cooperative program called Medicare Advantage. The success of the Medicare Advantage program is mostly due to the competition between these private insurers which lowers costs and improves the quality and range of services provided.

Medicare for All calls for the elimination of all private health insurance. There will be no competition and all healthcare decisions will be made by the government. The lack of competition will lead to lower quality, fewer services, and higher costs. With no competition, providers will be stuck with fixed rates and no means to appeal. As a result, providers will lose incentives to provide more than the minimum care needed. This trend is already prevalent in socialized medicine systems operating today in Canada and Great Britain.

We have the best quality healthcare in the world, though not the cheapest. Won’t we continue to have the best healthcare even with Medicare for All?

My friend and I agree that America leads the world in providing the best possible healthcare. He believes this will continue despite a change to socialized medicine. This is not the pattern we see when studying socialized medicine systems in other countries. Healthcare outcomes are dramatically worse in countries where the government controls all healthcare. We may have the best trained doctors in the world, but those doctors’ hands will be tied by government officials who will determine who gets care and what care they get. This is most dramatically seen in cancer screening and treatment.

Socialized medicine systems such as the United Kingdom and Canada don’t allow for expensive drugs and therefore these countries do not enjoy our cancer survival rates. The U.K.’s National Institute for Health and Care Excellence (a misnomer at best) has rejected immunotherapies because they are too expensive. Better healthcare comes at a price that socialized systems are not willing to pay.

As a result, these systems have lower cancer survival rates. The age-adjusted mortality rate is about 20% higher in the U.K. and 10% higher in Canada and France than in the U.S. Survival rates for hard -to-treat cancers are also higher in the U.S. than in most countries with nationalized health systems. The British medical journal Lancet  published last year that an individual diagnosed with pancreatic cancer between 2010 and 2014 had nearly twice the likelihood of surviving five years in the U.S. than in the U.K.

Here are some five-year survival comparisons:

  • Brain Cancer
    • S. – 36.5%
    • France – 27.2%
    • K. – 26.3%
  • Stomach Cancer
    • S. – 33.1%
    • France – 26.7%
    • K. – 20.7%

 

The availability of expensive drug treatments is only one reason for better survival rates in the U.S. Another reason is better methods of detecting cancer at earlier stages. MRI scanners are more widespread and available for earlier diagnosis. Other diagnostic advances include Google’s artificial intelligence (AI) that can now detect breast and lung cancers with better accuracy – meaning fewer false positives and negatives – than radiologists. AI systems are also enabling researchers to identify more genetic links and to personalize treatments.

With Medicare for All, all physicians will work for the government. Since we’ll have the same great doctors, won’t we still receive the same great healthcare?

Medicare for All will mean the government sets all prices for doctor services and approves or disapproves of all treatment. All doctors will have to accept the fee schedules set by the government or cease to practice medicine. Many older, experienced physicians will see this as an incentive to retire, or at least leave the clinical practice of medicine. This will strip many talented physicians from the work force.

They will be replaced by younger physicians without the experience or work ethic of some of our best physicians. These new physicians will be willing to accept the lower fees mandated by the government, but they will demand reduced hours and will produce less service. Combining these changes, the net result will be severe exacerbation of our physician shortage, which is already alarming.

But the real problem is the government will have to approve all treatment. It doesn’t matter how good your doctor is, he or she will be limited by government approval. Combining this feature of socialized medicine with an increasing doctor shortage leads to a common situation experienced in all socialized medicine systems.

All socialized medicine systems suffer from common ailments:

  • Delays in treatment– longer waiting times to see a physician
  • Rationing of healthcare– delays or denial of specialized care
  • Poorer healthcare outcomes– lower survival and life expectancy rates

 

Joe Biden tries to distance himself from Medicare for All by saying he just wants to “improve ObamaCare.” However, his platform calls for a “public option” to be added to ObamaCare, which simply means a slower timetable until socialized medicine is a reality. The end result is the same – total government control of healthcare.

Now he’s added Senator Kamala Harris to the ticket and she was one of the first presidential candidates to embrace Medicare for All, declaring openly it would mean the elimination of all private health insurance. Later, she tried to walk back her support when she received a backlash, but she will certainly support Biden’s move to socialized medicine over time.

Don’t be fooled. Medicare for All will mean the elimination of all private health insurance – which means Medicare for None.

 

(Note: For more on Medicare for All, use the Search feature on my blog to see earlier posts on this same subject.)

Convalescent Plasma Approved for Covid Treatment

 

The FDA has approved convalescent plasma for “emergency use authorization” (EUA) in treating Covid-19. This is an important tool in the medical treatment of this coronavirus and brings hope when it is seriously needed.

Naturally, those on the left and the mainstream media are accusing the FDA of playing politics with this decision. I guess this is expected since they play politics with every decision. But the FDA is merely approving what has been widely used by physicians for treating Covid-19 already; and has been in use for various illnesses since the late 19thcentury!

Ever since President Trump promoted hydroxychloroquine as a therapeutic treatment for Covid-19, the media and liberals have been out to prove him wrong and the same is happening with convalescent plasma. You would think that everyone would welcome an important breakthrough in the treatment of this dread disease, but many seem to be rooting for prolongation of the pandemic. It seems to fit their political agenda – at least until this November.

The Wall Street Journal editorial board says convalescent plasma has been used in the past to treat a wide range of illnesses including smallpox, the Spanish flu and Ebola as well as more recent respiratory viruses like H1N1, SARS, and MERS. The plasma is expected to help sick patients mount a stronger immune response by infusing them with plasma containing antibodies from recovered patients.

The immune system varies in every individual which explains why many exposed to the virus do not get sick while others do. The immune response also varies with convalescent plasma treatments; in some it produces significant improvement while others not much. This variation in response makes it difficult to evaluate effectiveness in randomized trials with control groups.

The evidence for convalescent plasma relies on more than a dozen observational studies and clinical trials that don’t meet the randomized placebo standard. One trial from Houston Methodist hospitals found that mortality among patients treated with convalescent plasma was more than 50% lower than for similar patients matched for age and underlying conditions. But the study population size wasn’t large enough to be statistically significant. Mortality was 83% loweramong a subset of patients transfused with plasma containing high levels of antibodies within 72 hours of hospital admission.

Perhaps the most persuasive evidence comes from a Mayo Clinic study, which has enrolled 90,000 hospitalized subjects since April. Although the study doesn’t include a placebo group for comparison, mortality was 21% lower among non-intubated patients treated with plasma containing high levels of antibodies versus lower levels.

Among a smaller subset of non-intubated patients below age 80 who were transfused within 72 hours of diagnosis, seven-day mortality was 44% lower among the high-antibody group. Yet the study when considering all patients did not find a difference in seven-day survival between patients transfused with higher or lower antibody plasma.

The FDA concludes, “This finding of a dose-response between antibody level and reduction in mortality provides evidence that the antibody is the active agent in convalescent plasma for treatment of Covid-19. Current evidence suggests that benefit is most likely in patients treated early in the course of the disease (e. g. prior to intubation).”

Convalescent plasma now joins remdesivir and dexamethasone as important advances in the treatment of Covid-19 until an effective vaccine is produced. The FDA was right to approve it for EUA at this time.

The Medical Cost of the Lockdown

 

We all know the lockdown imposed by our government to slow the spread of the coronavirus was devastating to our economy. Unemployment rose from an historic low of 3.8% to 13% on average and even higher for women (14.3%), blacks (17.2%) and Hispanics (19.5%) according to the Pew Research Center. The booming Trump economy was voluntarily halted in the interest of controlling the virus.

 

The Wall Street Journal editorial board says Democratic Presidential nominee Joe Biden was recently asked if he were in charge, would he call for another lockdown. His response, “I would shut it down. I would listen to the scientists.” Is that the correct decision?

Scientists have been used as scapegoats for many who want to justify their policy decisions, but which scientists do you follow? The scientists said masks were unnecessary early, and even prohibited except for medical personnel and first-responders. Today we’re all told to wear masks, even in circumstances that don’t make scientific sense such as riding your bicycle or walking your dog. Biden wants to make mask-wearing a national mandate, even though he doesn’t have the Constitutional authority to demand that.

But what about the medical cost of the lockdown? While the lockdown probably slowed the spread of the virus and avoided medical rationing of services, a real cost was being paid for limiting other medical services, like cancer screening, diabetes control, and cardiac testing, just to name a few. Now we have an answer to that question.

Undetected Cancer

The Journal of the American Medical Association (JAMA) just published a report that newly identified cancers fell 46.4% from March 1 to April 18. That doesn’t mean there are fewer cancers – just that they aren’t being detected! This drop in detected cancers means those cancers will be diagnosed later at advanced stages when clinical outcomes will be worse.

Stress-induced Cardiomyopathy

The Cleveland Clinic last month reported the incidence of stress-induced cardiomyopathy from March 1 to April 30 increased four-fold. Tufts Medical Center last month warned that psychological distress, fear and emotional stress, “coupled with worse clinical outcomes when patients avoid seeking effective care, creates a double hit from this pandemic in which morbidity and mortality associated with cardiac disease might well overtake the risks directly linked to the virus itself.”

Substance Abuse

The Centers for Disease Control and Prevention (CDC) last week reported that 13.3% of Americans in June said they had increased substance use to cope with pandemic-related stress. About half of those ages 18 to 24 reported severe anxiety and depression, and a quarter said they had seriously considered suicide in the last 30 days.

Domestic Violence

A new study from Brigham and Women’s Hospital in Boston reports a spike in injuries indicative of domestic abuse, especially severe injuries from strangulation and use of weapons, from March 11 to May 3.

The JAMA report was summarized by epidemiologist Tyler J. VanderWeele of Harvard’s T.H.Chan School of Public Health: “While confronting the possibility of a second wave of the pandemic, these calculations of total lives lost, both from SARS-CoV-2 (Covid-19) infection and because of social, psychological, and unemployment outcomes, may prove important in policy decisions.”

The WSJ editors say, “Mr. Biden says he’d order another shutdown if scientists say it would save lives. But by that standard he’d have to keep the economy constrained for months and for many contagious diseases. He wants to blame Mr. Trump for unemployment but another lockdown would cost millions more jobs. A President has to consider the larger national interest, and that means listening to economists and health experts beyond epidemiologists. Mr. Biden’s comments misjudge the duty of a President.”

As a physician with scientific training, I certainly respect science and its importance when evaluating and treating disease. But decisions about treating one disease must always be weighed against the impact that treatment will have on other medical conditions. We cannot celebrate the elimination of one disease if our treatment kills the patient.